WHAT IS CLAIMED IS:

1. A pharmaceutical formulation for topical treatment of a skin disease, comprising:
   (a) a JAK1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof; and
   (b) a vitamin D3 analog, which is calcipotriol or maxacalcitol.

2. The pharmaceutical formulation of claim 1, wherein the JAK1/2 inhibitor is ruxolitinib, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog is calcipotriol.

3. The pharmaceutical formulation of claim 1, wherein the JAK1/2 inhibitor is ruxolitinib, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog is maxacalcitol.

4. The pharmaceutical formulation according to any one of claims 1-3, wherein the formulation comprises from about 0.05% to about 3.0% or about 0.05% to about 1.5% w/w of the ruxolitinib, or the pharmaceutically acceptable salt thereof, on a free base basis.

5. The pharmaceutical formulation according to any one of claims 1-3, wherein the formulation comprises about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1.0%, about 1.05%, about 1.1%, about 1.15%, about 1.2%, about 1.25%, about 1.3%, about 1.35%, about 1.4%, about 1.45%, about 1.5%, about 1.55%, about 1.6%, about 1.65%, about 1.7%, about 1.75%, about 1.8%, about 1.85%, about 1.9%, about 1.95%, about 2.0%, about 2.5%, or about 3.0% by weight of the formulation on a free base basis of the ruxolitinib, or the pharmaceutically acceptable salt thereof.

6. The pharmaceutical formulation of any one of claims 1-5, wherein the formulation comprises from about 0.0001% w/w to about 0.01% w/w of the vitamin D3 analog on a free base basis.

7. The pharmaceutical formulation of any one of claims 1-5, wherein the formulation comprises from about 0.0001% w/w to about 0.005% w/w of the vitamin D3 analog on a free base basis.

8. The pharmaceutical formulation of any one of claims 1-5, wherein the formulation comprises from about 0.0001% w/w to about 0.01% w/w or from about 0.0001% w/w to about 0.005% w/w of the vitamin D3 analog on a free base basis.

9. The pharmaceutical formulation of any one of claims 1-5, wherein the formulation comprises about 0.005% w/w of the vitamin D3 analog on a free base basis.

10. The pharmaceutical formulation of any one of claims 1-9, wherein the formulation is a cream or a lotion.

11. The pharmaceutical formulation of any one of claims 1-10, wherein the formulation is an oil-in-water emulsion.

12. The pharmaceutical formulation of any one of claims 1-11, wherein the formulation comprises water, an oil component, and an emulsifier or a stabilizer component.

13. The pharmaceutical formulation of claim 12, wherein the water comprises from about 5% to about 90%, from about 10% to about 80%, from about 10% to about 70%, from about 10% to about 60%, about 20% to about 70%, about 20% to about 60%, or from about 20% to about 50% by weight of the pharmaceutical formulation.

14. The pharmaceutical formulation of any one of claims 12-13, wherein the oil component comprises from about 5% to about 90%, from about 5% to about 80%, from about 5% to about 70%, from about 5% to about 60%, from about 5% to about 50%, or from about 5% to about 40% by weight of the pharmaceutical formulation.

15. The pharmaceutical formulation of any one of claims 12-14, wherein the emulsifier or stabilizer component comprises from about 1% to about 30% or from about 5% to about 25% by weight of the pharmaceutical formulation.

16. The pharmaceutical formulation of any one of claims 12-15, further comprising a solvent component for dissolving ruxolitinib, or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical formulation of claim 16, wherein the solvent component comprises from about 5% to about 20%, from about 2% to about 30%, from about 5% to about 30%, from about 5% to about 25%, from about 5% to about 20%, or from about 10% to about 20% by weight of the pharmaceutical formulation.

18. The pharmaceutical formulation of any one of claims 1-17, wherein the formulation has a pH of from about 6.0 to about 8.0, from about 6.5 to about 7.5, or from about 6.5 to about 7.0.

19. The pharmaceutical formulation of claim 18, wherein pH of the formulation is adjusted with trolamine.

20. The pharmaceutical formulation of any one of claims 1-19, wherein the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.

21. Use of (a) a JAK1/2 inhibitor which is ruxolitinib, or a pharmaceutically acceptable salt thereof and (b) a vitamin D3 analog, which is calcipotriol or maxacalcitol in the manufacture of a pharmaceutical formulation for treating a skin disease in a patient in need thereof.

22. The use of claim 21, wherein the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.

23. The use of claim 21, wherein the JAK1/2 inhibitor is ruxolitinib, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog is calcipotriol.

24. The use of claim 21, wherein the JAK1/2 inhibitor is ruxolitinib, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog is maxacalcitol.

25. The use of any one of claims 21-24, wherein the skin disease is selected from one or more of the following: an autoimmune or an inflammatory skin disease; a skin disease that is a

Th1 or Th17 associated skin disease; a skin disease that is mediated by interleukin 22 (IL-22), C-X-C motif chemokine 10 (CXCL10), matrix metallopeptidase 12 (MMP12), or a combination thereof; a skin disease that is mediated by Defb4, S100a12, or Serpinb4; a skin disease that is mediated by filaggrin/FLG, Loricin/LOR, IL-31, TSLP, CAMP, CCL17, CCL22, DefB4a, interferon-gamma, IL-17A, IL-17F, IL-22, IL-33, IL-4, or TNFSF18; a skin disease that is selected from psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, and ichthyosis; or a skin disease that is selected from rosacea, psoriatic arthritis, dermal fibrosis, morphea, spitz nevi, dermatophytosis, or acne vulgaris.

26. The use of any one of claims 21-25, wherein there is a synergistic effect between the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog, or the pharmaceutically acceptable salt thereof.

27. The use of any one of claims 21-26, wherein the pharmaceutical formulation is formulated such that (a) the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, and (b) the vitamin D3 analog are to be administered at least one time per day.

28. The use of any one of claims 21-26 wherein the pharmaceutical formulation is formulated such that (a) the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, and (b) the vitamin D3 analog are to be administered at least two times per day.

29. The use of any one of claims 21 to 28, wherein the pharmaceutical formulation is formulated such that the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog are to be administered in a topical formulation.

30. The use of claim 29, wherein the pharmaceutical formulation is formulated such that the JAK1/2 inhibitor, or the pharmaceutically acceptable salt thereof, and the vitamin D3 analog are to be administered in a single topical formulation.

31. The use of claim 30, wherein the single topical formulation is an ointment, a cream, or a lotion.

32. The use of claim 31, wherein the single topical formulation has a pH of from about 6.0 to about 8.0, from about 6.5 to about 7.5, or from about 6.5 to about 7.0.

33. The use of any one of claims 21-32, wherein the pharmaceutical formulation is formulated to be administered with a corticosteroid.

34. The use of claim 33, wherein the corticosteroid is betamethasone dipropionate.